The term dark proteome covers an astonishing diversity of molecular species. It includes proteins translated from non-canonical open reading frames — stretches of RNA that were long dismissed as non-coding filler — as well as products of repeat elements such as endogenous retroviruses and LINE-1 transposons, peptides derived from circular RNAs, mistranslated proteins produced when the ribosome inserts the wrong amino acid, proteasomally spliced peptides, and stress-induced translation products that appear only when cells are pushed to the brink. Over the past decade, an unprecedented depth of resolution has been attained in cataloguing this hidden world, with individual classes of dark proteins now numbering in the thousands of members each. A massive proteogenomic screen published in 2024, for example, identified thousands of novel peptides from the human dark proteome, and a 2026 study in Nature expanded the human proteome with microproteins and peptideins — molecules with evidence for their existence but ambiguous or absent evidence for physiological function in normal cells.

The technological engine behind this discovery wave is ribosome profiling, or Ribo-seq, a technique first developed in Weissman’s laboratory that captures snapshots of every ribosome engaged on every messenger RNA in a cell. Ribo-seq revealed that translation is far more pervasive than textbook models suggested: ribosomes initiate not only at annotated start codons but at hundreds of thousands of upstream and alternative sites, in long non-coding RNAs, in 5′ untranslated regions and even in pseudogenes. Complementing Ribo-seq, immunopeptidomics — the mass spectrometric analysis of peptides presented on the cell surface by major histocompatibility complex molecules — has shown that a striking fraction of the peptides displayed by cancer cells comes from these unannotated sources. Studies in melanoma, lung cancer and pancreatic cancer have demonstrated that noncoding and non-canonical regions are among the main sources of targetable tumour-specific antigens, fundamentally challenging the assumption that neoantigens arise mainly from point mutations in canonical genes.

What makes the dark proteome more than a curiosity is the accumulating evidence that its members do real work in cancer biology. Individual dark proteins have now been characterized as oncogenes, tumour suppressors, signalling regulators and cancer-specific genetic dependencies. The microprotein TPM3P9, encoded by a cryptic long non-coding RNA, drives oncogenic RNA splicing and tumorigenesis. The TINCR ubiquitin-like microprotein acts as a tumour suppressor in squamous cell carcinoma, while a related microprotein called pTINCR promotes epithelial differentiation and suppresses tumour growth through activation of the CDC42 protein. In glioblastoma, a peptide encoded by the upstream open reading frame of the MYC messenger RNA binds to the tropomyosin receptor kinase B and promotes tumour growth in mice, and the upstream-ORF-encoded MP31 disrupts mitochondrial quality control and inhibits tumorigenesis. In childhood medulloblastoma, translation of non-canonical open reading frames appears to function as a cancer cell survival mechanism in its own right.

Perhaps the most dramatic examples come from dual-coding genes — loci where a single stretch of DNA yields both a canonical protein and a second, unconventional product. The NCYM gene, a cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β and thereby stabilizes MYCN in human neuroblastomas, a finding that has been linked to clinical outcome. The classic CDKN2A tumour suppressor locus encodes not only p16INK4A but also p14ARF, an alternative reading frame product that forms meso-scale assemblies upon phase separation with the nucleolar protein NPM1. Even the circular RNA world has yielded a functional oncogene: Firefox, a protein encoded by circular PVT1 RNA, was shown in 2026 to be essential for MYC-driven oncogenesis. These cases demonstrate that the dark proteome is not merely translational noise but a layer of biology with direct consequences for tumour evolution and treatment response.

How does cancer gain access to this hidden protein repertoire? The Perspective outlines several mechanisms of dysregulation. Oncogenic transcription factors, particularly chimeric fusion proteins characteristic of certain leukaemias and sarcomas, can drive tumour-specific transcription, processing and translation of silent genomic regions, effectively switching on genes that were never meant to be expressed. Extrachromosomal DNA — circular DNA molecules that carry amplified oncogenes such as MYC in pancreatic cancer — can generate fusion transcripts and aberrant translation products at high levels. Nutrient stress provides another route: when tumours experience tryptophan or arginine deprivation, the ribosome misincorporates substitute amino acids, generating so-called substitutants that are foreign to the immune system. Chemotherapy and leucine deprivation likewise induce codon-biased aberrant protein production. Meanwhile, oncogene-driven sloppiness in mRNA translation, ribosomal frameshifting and stress-response pathways such as the integrated stress response and the unfolded protein response all conspire to flood the cancer cell with non-canonical peptides, many of which end up displayed on the cell surface.

It is on the immunotherapy front that the dark proteome may deliver its most immediate clinical payoff. Because many dark proteins are encoded by genomic regions that are not expressed in healthy tissues, the immune system has never been trained to tolerate them, making their peptides potentially ideal tumour antigens. Endogenous retrovirus-derived antigens have already been shown to promote lung cancer immunotherapy, and antibodies against these ancient viral proteins correlate with response to checkpoint blockade. Shared epitopes from endogenous retroviruses can induce high-avidity cytotoxic T cells, and tumour circular RNAs have been shown to elicit anti-tumour immunity by encoding cryptic peptides. In pancreatic cancer, tumour-restricted cryptic antigens have been validated as targets for T cell recognition. The therapeutic modalities now in play span the full modern immunotherapy arsenal: personalized and shared vaccines, TCR-engineered T cells, CAR-T cell approaches and bispecific T cell engagers. A first-in-class bispecific T cell engager targeting a DARKFOX peptide presented by solid tumours has already entered preclinical development, and a clinical trial of a dark-proteome-directed immunotherapy is registered on ClinicalTrials.gov.

Turning dark proteins themselves into drug targets is harder, but not impossible. Many are small, intrinsically disordered molecules that lack the stable pockets conventional small-molecule drugs require. Yet structure prediction tools such as AlphaFold, together with new protein design methods for binding intrinsically disordered regions, are beginning to make the undruggable tractable. The MYC inhibitor omomyc — a miniprotein that exploits intrinsic cell-penetrating activity — has advanced to a phase 1 clinical trial in solid tumours, and a synthetic cell-penetrant miniprotein called DuoMYC efficiently inhibits oncogenic MYC. EMBOW-derived peptides targeting the WDR5-MLL1 complex have suppressed leukaemia progression in preclinical models. Functional genomics is doing the other half of the work: CRISPR-based screens have revealed that human cancer cells depend on cryptic non-canonical open reading frames, and large-scale short open reading frame screens have identified microproteins involved in cancer cell fitness, feeding into resources such as the cancer dependency map and the dark kinase knowledgebase.

The authors are careful to emphasize how much remains unknown. Key gaps persist in understanding how the dark proteome is regulated, how much it actually contributes to cancer phenotypes versus representing tolerated noise, how antigenic its products truly are in patients, and whether dark proteins can be developed into clinical-grade therapies with acceptable safety profiles. Community efforts to standardize the annotation of translated open reading frames, benchmark mass spectrometric detection of unannotated microproteins and expand reference catalogues such as GENCODE are underway, supported by initiatives including the Cancer Grand Challenges dark proteome teams. Spatial transcriptomics and single-cell Ribo-seq are adding tissue-level context, revealing where and when unconventional translation occurs in intact tumours. What is clear is that the dark proteome offers the possibility to advance cancer science, diagnosis and treatment in ways the genomics revolution alone could not. The darkness, the authors suggest, is not a void but an unexplored continent — and the maps are finally being drawn.

Subject of Research: The functional dark proteome in cancer, comprising non-canonical proteins and peptides with roles in tumour biology and immunotherapy

Article Title: Mapping the functional dark proteome in cancer

Article References: Prensner, J. R., Freed-Pastor, W. A., Abelin, J. G., Wu, C. J., Merbl, Y., Pilpel, Y., Schumacher, T. N., Weissman, J. S., van Heesch, S., & Agami, R. (2026). Mapping the functional dark proteome in cancer. Nature Reviews Cancer. https://doi.org/10.1038/s41568-026-00985-1

Image Credits: AI Generated

DOI: 10.1038/s41568-026-00985-1

Keywords: dark proteome, cancer, non-canonical open reading frames, microproteins, Ribo-seq, immunopeptidomics, neoantigens, cancer immunotherapy, CRISPR screens, tumour suppressors, oncogenes, translational dysregulation

At the heart of this discovery lies the concept of non-canonical open reading frames (ncORFs)—segments of DNA that do not conform to the established criteria for protein-coding sequences. Historically, proteins have been defined primarily by their size and evolutionary conservation, with databases cataloging roughly 19,500 recognized human proteins. Yet this binary framework is proving insufficient. By mining over 7,200 ncORFs through a massive computational analysis involving 95,520 experimental datasets spanning approximately 20,000 hours of nonstop computation, the research consortium identified 1,785 novel microproteins, drastically expanding the known proteome by nearly 10%.

What sets these microproteins apart from their traditional counterparts is their diminutive size: about 65% of the newly identified peptideins contain fewer than 50 amino acids, whereas less than 1% of established proteins fall within this range. This stark difference not only challenges pre-existing protein definitions but also complicates functional annotation. Intriguingly, only a handful of these microproteins resemble known proteins structurally, suggesting that most peptideins represent a distinct biological category with potentially diverse and unconventional roles.

To address this conundrum, the researchers conceptualized peptideins as a third biological category alongside proteins and non-coding DNA sequences, reflecting a nuanced view where DNA can produce traditional proteins, peptideins, or nothing at all. Crucially, peptideins are protein-like molecules composed of amino acids that reside within cells, yet their functional significance is enigmatic. They may perform vital biological tasks, remain inert byproducts, or represent intermediates awaiting further characterization. This tentative classification invites the scientific community to investigate their roles more deeply.

Capitalizing on cutting-edge CRISPR gene editing technologies, the consortium conducted large-scale functional screens that spotlighted six peptideins critical for cellular survival—referred to as pan-essential peptideins. One standout peptidein, derived from the OLMALINC genetic locus previously discounted as non-coding, was shown to be indispensable for over 85% of more than 485 diverse cancer cell lines tested. This peptidein modulates fundamental cellular processes such as cell division and DNA damage repair, underscoring its potential as a therapeutic target.

Beyond their intracellular functions, many peptideins appear on the surfaces of cells where they might interact with the immune system, rendering them promising candidates for cancer immunotherapies. The ability of these peptideins to act as neoantigens—unique markers recognized by immune cells—could pave the way for novel vaccines and targeted treatments that harness the body’s own defenses to eliminate malignant cells. Pharmaceutical interest is mounting, with several peptidein-derived molecules already progressing through drug development pipelines.

The newfound recognition of peptideins also promises to illuminate obscure genetic diseases that have resisted explanation by traditional genomic analyses. Because peptidein-coding regions were historically ignored or misclassified as non-functional, their pathogenic roles have remained hidden. Incorporating peptideins into genetic diagnostics could therefore enhance the detection and understanding of heretofore enigmatic disorders, enabling more accurate diagnosis and potentially unveiling novel therapeutic avenues.

A compelling case study further reinforcing the biological importance of these small molecules emerged from prior research on ASNSD1-uORF, a microprotein instrumental in a high-risk pediatric brain cancer called medulloblastoma. The Princess Máxima Center for Pediatric Oncology is currently extending this line of investigation into other pediatric tumors, including neuroblastoma, especially those exhibiting activation of the MYC oncogene. These efforts underscore how peptideins can provide critical mechanistic insights into cancer biology, informing the development of precision oncology strategies.

Leading the charge at the Princess Máxima Center, Dr. Sebastiaan van Heesch points out that the traditional protein catalog significantly underrepresents the diversity of molecular actors within human cells. The classification of peptideins confers a formal status to these enigmatic molecules, enabling their systematic inclusion in reference databases and fostering a wave of research endeavors worldwide. He anticipates peptideins will swiftly emerge as central figures in drug discovery and cellular immunotherapy development, especially given their prevalence across varied tissues and pathological contexts.

Echoing this optimism, Dr. John Prensner from the University of Michigan Medical School describes the unveiling of the dark proteome as an early “trailer” to a groundbreaking cinematic release, signaling transformative changes in biological science and medicine. The untapped wealth of peptideins holds promise for revolutionizing approaches to complex diseases, cancer foremost among them.

Dr. Robert Moritz of the Institute for Systems Biology further elaborates on the magnitude of this achievement, emphasizing the decades-long investments in computational infrastructure and analytic pipelines that rendered this proteomic expansion feasible. His team’s deployment of the Trans Proteomic Pipeline across massive-scale mass spectrometry datasets has validated peptidein existence with unprecedented confidence. Importantly, Moritz envisions peptideins as just the beginning of a vast, unexplored molecular landscape, suggesting that these versatile regulators could revolutionize our understanding of gene regulation, signaling networks, and cellular persistence.

Together, this international consortium—comprising more than 60 scientists across 30 institutions, including the Princess Máxima Center, University of Michigan, EMBL’s European Bioinformatics Institute, and the Institute for Systems Biology—has created an open-access resource to accelerate worldwide peptidein research. Their work exemplifies how collaboration, computational prowess, and innovative biology converge to illuminate previously invisible dimensions of human molecular architecture, with profound implications for diagnostics, therapeutics, and fundamental biology.

As peptideins take their place on the molecular stage, the scientific and medical communities stand on the cusp of redefining long-held dogmas. This discovery not only expands the human proteome but catalyzes a paradigm shift, fostering new avenues to decode the complexity of life and disease. The dark proteome, once a biological blind spot, is now a vibrant frontier promising to unlock transformative biomedical innovations.

Subject of Research: Cells

Article Title: Expanding the human proteome with microproteins and peptideins

News Publication Date: 6-May-2026

Web References:

• DOI: 10.1038/s41586-026-10459-x

Image Credits: Leron Kok/Princess Máxima Center for pediatric oncology

Keywords: Proteomics, Protein functions, Molecular targets, Drug targets, Cancer